Long-term treatment with ofatumumab, a fully human anti-CD20 monoclonal antibody, is associated with a favourable safety profile and sustained efficacy, according to a newly-published analysis of the ALITHIOS long-term extension (Hauser et al. Mult Scler 2023; epublished September 11, 2023). The study is the most recent to support the earlier use of high-efficacy therapy in patients with multiple sclerosis. Read More
This year’s joint ECTRIMS-ACTRIMS congress will be held on October 11-13 in Milan, Italy. We are currently surveying readers about their key interests beforehand as a guide to our coverage. Daily highlights will be posted on October 12-14. Click here to complete the survey to tell us what topics are of greatest interest to you. Read More
Help make the NeuroSens coverage of MSMilan 2023 (The 9th Joint ECTRIMS-ACTRIMS Meeting) relevant to you.
Complete the survey below to tell us what topics are of greatest interest to you. Read More
A new study has reported that the kappa free light chain index (K-index) can predict the occurrence of new T2 lesions in subjects with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) (Levraut et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200156). The K-index was also useful to predict clinical events in CIS. Read More
The TERIS trial of teriflunomide in individuals with radiologically isolated syndrome (RIS) has reported that treatment significantly prolonged the time to a first clinical event by 63% versus placebo (Lebrun-Frenay et al. JAMA Neurol, epublished August 21, 2023). Read More